Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Clinical trial NCT07032129 · RECRUITING

Trial details

NCT number: NCT07032129
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma Progression Multiple Myeloma, Refractory

Start date: 2025-04-29
Primary completion: 2027-12-10
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.